BMRN vs POST · P/E 40, rev $2.85B vs P/E 15, rev $8.16B
Biomarin Pharmaceutical Inc (BMRN) versus Post Holdings Inc (POST) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Post Holdings Inc (POST) is a packaged foods company listed on NYSE.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported POST revenue for 2025-09-30 was $8.16B. Net income was $335.8M. Revenue was up 3.0% from 2024-09-30 to 2025-09-30. POST currently screens at market cap $4.03B and trailing P/E 14.9.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. POST currently screens at market cap $4.03B and trailing P/E 14.9.
Not investment advice. Open the BMRN and POST stock pages for the full models.
Not investment advice.